NovoCure Ltd (NASDAQ: NVCR) kicked off on Tuesday, up 5.97% from the previous trading day, before settling in for the closing price of $15.58. Over the past 52 weeks, NVCR has traded in a range of $11.70-$34.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12.60% over the past five years. While this was happening, its average annual earnings per share was recorded -27.20%. With a float of $98.34 million, this company’s outstanding shares have now reached $108.52 million.
Let’s look at the performance matrix of the company that is accounted for 1488 employees. In terms of profitability, gross margin is 77.33%, operating margin of -28.18%, and the pretax margin is -21.67%.
NovoCure Ltd (NVCR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 10.53%, while institutional ownership is 86.21%. The most recent insider transaction that took place on Mar 03 ’25, was worth 5,071. In this transaction Chief Innovation Officer of this company sold 268 shares at a rate of $18.92, taking the stock ownership to the 166,243 shares. Before that another transaction happened on Mar 03 ’25, when Company’s EVP, Pres., Novocure Oncology sold 2,527 for $18.54, making the entire transaction worth $46,841. This insider now owns 143,673 shares in total.
NovoCure Ltd (NVCR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -27.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.18% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Take a look at NovoCure Ltd’s (NVCR) current performance indicators. Last quarter, stock had a quick ratio of 1.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -2.01 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
NovoCure Ltd (NASDAQ: NVCR) saw its 5-day average volume 0.81 million, a negative change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 44.91%. Additionally, its Average True Range was 1.01.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 8.80%, which indicates a significant decrease from 54.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.52% in the past 14 days, which was lower than the 87.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.04, while its 200-day Moving Average is $20.37. Nevertheless, the first resistance level for the watch stands at $16.74 in the near term. At $16.97, the stock is likely to face the second major resistance level. The third major resistance level sits at $17.34. If the price goes on to break the first support level at $16.14, it is likely to go to the next support level at $15.77. Assuming the price breaks the second support level, the third support level stands at $15.54.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
The company with the Market Capitalisation of 1.81 billion has total of 109,915K Shares Outstanding. Its annual sales at the moment are 605,220 K in contrast with the sum of -168,630 K annual income. Company’s last quarter sales were recorded 161,270 K and last quarter income was -65,920 K.
